Key result
Combined aspirin and ticlopidine blocked platelet thrombus formation on collagen by >90% compared to placebo or either drug alone (P<0.01), but did not inhibit thrombus on tissue factor surfaces.
Why the study?
Does combined aspirin and ticlopidine therapy reduce experimental arterial thrombogenesis compared to either drug alone or placebo in healthy male volunteers?
Population
16 healthy male volunteers
Comparison
Aspirin 325 mg/d + ticlopidine 500 mg/d for 8 days vs Aspirin 325 mg/d alone, ticlopidine 500 mg/d…
Design
RCT, randomized, double-blind
Follow-up
8 days per treatment period
Authors
Loading...
Supports dual antiplatelet use for collagen-exposed thrombosis; extends single-agent data to synergistic regimens in this RCT.
RCT (n=16)
Double-blind
randomized
Does combined aspirin and ticlopidine therapy reduce experimental arterial thrombogenesis compared to either drug alone or placebo in healthy male volunteers?
Effect estimate: >90% reduction
p-value: p=<.01
Combined aspirin and ticlopidine therapy synergistically inhibits platelet thrombus formation on collagen surfaces ex vivo compared to either agent alone.
Bossavy et al. (1998) conducted an RCT in Healthy volunteers (n=16). Combined aspirin and ticlopidine vs. Aspirin alone, ticlopidine alone, and placebo was evaluated on Platelet thrombus formation on collagen-coated coverslips (>90% reduction, p=<.01). Combined aspirin and ticlopidine blocked platelet thrombus formation on collagen by >90% compared to placebo or either drug alone (P<0.01), but did not inhibit thrombus on tissue factor surfaces.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: